CN106800641A - A kind of mPEG-b-PCL diblock polymers polymer and its application and preparation - Google Patents

A kind of mPEG-b-PCL diblock polymers polymer and its application and preparation Download PDF

Info

Publication number
CN106800641A
CN106800641A CN201610494508.0A CN201610494508A CN106800641A CN 106800641 A CN106800641 A CN 106800641A CN 201610494508 A CN201610494508 A CN 201610494508A CN 106800641 A CN106800641 A CN 106800641A
Authority
CN
China
Prior art keywords
mpeg
pcl
polyethylene glycol
diblock polymer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610494508.0A
Other languages
Chinese (zh)
Other versions
CN106800641B (en
Inventor
师健友
闫俊峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Provincial Peoples Hospital
Original Assignee
Sichuan Provincial Peoples Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Provincial Peoples Hospital filed Critical Sichuan Provincial Peoples Hospital
Priority to CN201610494508.0A priority Critical patent/CN106800641B/en
Publication of CN106800641A publication Critical patent/CN106800641A/en
Application granted granted Critical
Publication of CN106800641B publication Critical patent/CN106800641B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a kind of diblock polymer of polyethylene glycol crosslinked polycaprolactone, its structural formula is mPEG b PCL, and wherein mPEG and PCL molar ratios are 1：0.1~1：10.The diblock polymer of polyethylene glycol crosslinked polycaprolactone of the invention has good load medicine potentiality, can carrying medicament steady running, to the target spot of target, realizes the dispersion application of insoluble drug in vivo.And, the diblock polymer produces Adhesion inhibiyive effect for human body tumour cell or cancer cell so that tumor patient, the chemotherapeutic treatment effect of cancer patient are obviously improved.

Description

A kind of mPEG-b-PCL diblock polymers polymer and its application and preparation
Technical field
The present invention relates to a kind of diblock polymer of polyethylene glycol crosslinked polycaprolactone, more particularly to polyethylene glycol crosslinked gathers in oneself The preparation and its application of the diblock polymer of ester.
Background technology
Because of it, the small clinical practice for causing medicine of the solubility in water is restricted poorly water soluble drugs.Poorly water soluble drugs are passed through Some carriers are wrapped up, and are a kind of effective methods that poorly water soluble drugs are carried out with solubilising.
The size of amphiphatic molecule copolymer, stability, versatility and biocompatibility are all very outstanding, this cause they Drug delivery carrier and field of environment protection have very huge potentiality.In numerous amphiphilic polymers, especially with life The copolymer of thing compatibility and biological degradability, such as PLA-PEG, PCL-PEG, PCL-PLA-PEG, performance is the most prominent and robs Eye.
It is well known that the copolymer of amphiphatic molecule can be self-assembly of a hydrophobic core and hydrophilic shell in the solvent of selectivity Micelle, such micelle size is typically smaller than 200nm, the characteristic with part nano material.Amphiphilic diblock polyphosphazene polymer The characteristics of compound, makes micelle under the conditions of no additional stabilization agent hydrophilic when outside hydrophilic shell reaches maximum biological solubility Property solvent in keep dissolving when, hydrophobic nuclear interaction, so as to load some medicines for being insoluble in water.
Used as the carrier of dewatering medicament, the colloid of diblock polymer is widely studied.At present, micelle paper and data master are studied Focus on the release feature of the preparation of polymer, the effect between sign, medicine and carrier and medicine.In fact, so far Untill it is still very limited for the research of the degraded of copolymerization micelle.
There are some researches show PCL-PEG films can show extremely different hydrolytic degradation characteristics, and table with vitro in vivo Bright PCL-PEG films hydrolyze degradation process, may be influenceed by PEG molecule contents, environment temperature, acidity and basicity. Research finds that the degraded mode of PCL-PEG micelles and the degraded mode of discrete material are different, may have many potential Value.
The content of the invention
It is an object of the invention to be directed to not abundant enough, the existing diblock of the research on diblock polymer in the prior art The potential value exploitation of polymer is incomplete, there is provided a kind of new mPEG-b-PCL diblock polymer polymer.Meanwhile, The present invention provides the method for preparing this diblock polymer compound, and property to this diblock polymer compound is carried out Research is characterized, the potential medical value of this macromolecular compound is disclosed.
In order to realize foregoing invention purpose, the invention provides following technical scheme：
A kind of diblock polymer of polyethylene glycol crosslinked polycaprolactone, its composition structure is mPEG-b-PCL, wherein mPEG It is 1 with PCL molar ratios：0.1~1：10.
The diblock polymer of polyethylene glycol crosslinked polycaprolactone of the invention has good load medicine potentiality, can carrying medicament exist Steady running realizes the dispersion application of insoluble drug to the target spot of target in organism.And, the diblock polymer for Human body tumour cell or cancer cell produce Adhesion inhibiyive effect so that tumor patient, the chemotherapeutic treatment effect of cancer patient are shown The lifting of work.
There is the ester bond in polycaprolactone in PEG-b-PCL diblock copolymers hydrolysis of the present invention so that the molecular weight distribution of compound, Crystallinity etc. there occurs larger change.In the degradation process of PEG-b-PCL diblock copolymers, the molecule segment of polymer Hydrolytic cleavage mechanism be totally different from general polyethylene glycol compound so that the stability of compound, Drug loading capacity have pole Big lifting.
Further, preferably mPEG and PCL mass ratios are 1：1~1：6.When both ratios meet range above, two Block polymer can show more suitable stability, degradation property so that the stability and rate of release of medicine more preferably, Preferably promote the curative effect of medicine.When both ratios are 1：When 1, diblock polymer has good for the state of aggregation of cell Facilitation, there is certain inhibitory action simultaneously for the coherent condition of tumour cell, cancer cell, it is possible to increase chemotherapy Effect.
The present invention also provides a kind of method for preparing described diblock polymer simultaneously, comprises the following steps：
(1) taking polyethylene glycol, is dissolved in toluene, is dehydrated at 120-150 DEG C 1-3 hours, is preferably dehydrated 1.5-3 at 125-145 DEG C Hour.
(2) ε-hexamethylene lactone and stannous octoate, nitrogen is added to protect, 130-160 DEG C is reacted 8-16 hours.Preferably, exist 135-155 DEG C is reacted 8-15 hours.
(3) after reaction terminates, room temperature is cooled to, adds methyl tertiary butyl ether(MTBE), it is ultrasonic 5-30 minutes, under ice bath, cooling weight Crystallization 10-30 minutes, suction filtration collects filter residue, and vacuum drying both obtains target product.
The diblock polymer for obtaining is synthesized by above method and is target product of the invention, with good stability and knot Brilliant performance, can be effectively applied to the load medicine of insoluble drug.And, method made above is simple and easy to apply, and reaction efficiency is high, Substantially free of impurities is generated, the easily separated easy purification of product.
Application of the diblock polymer of above-mentioned polyethylene glycol crosslinked polycaprolactone in treating cancer or tumour medicine is prepared.This The diblock polymer of the polyethylene glycol crosslinked polycaprolactone of invention can effectively suppress the adhesion of cancer cell, tumour cell, make It keeps building up state, prevents the diffusion of cancer cell or tumour cell, improves therapeutic effect of the medicine for relevant disease.
Further, application of the diblock polymer of described polyethylene glycol crosslinked polycaprolactone in treatment breast cancer medicines are prepared. Research display diblock polymer of the invention can play good suppression aggtegation for breast cancer cell line MCF-7.
Further, the diblock polymer of described polyethylene glycol crosslinked polycaprolactone is as medicine carrying material in treating cancer or tumour Medicine in application.
Further, the nitrogen gas purity that described nitrogen protection is used is more than 99.99% High Purity Nitrogen.
Compared with prior art, beneficial effects of the present invention：
1. the diblock polymer of polyethylene glycol crosslinked polycaprolactone of the invention can be realized effectively for insoluble drug Load, transhipment, and ensure the dispersion of insoluble drug.
2. diblock polymer of the invention produces Adhesion inhibiyive effect for human body tumour cell or cancer cell so that tumour is suffered from Person, the chemotherapeutic treatment effect of cancer patient are obviously improved.
3. the preparation method that the present invention is provided is simple and easy to apply, and reaction efficiency is high, substantially free of impurities generation, the easily separated easy purification of product, Can be with popularization and application and various pharmaceutical preparations.
Brief description of the drawings：
Fig. 1 is mPEG-b-PCL diblock copolymers1H NMR spectras.
Fig. 2 is mPEG-b-PCL (MmPEG：MPCL=1：1) diblock copolymer1H NMR spectras.
Fig. 3 is mPEG-b-PCL (MmPEG：MPCL=1：4) diblock copolymer1H NMR spectras.
Fig. 4 is mPEG-b-PCL (MMPEG:MPCL=1:6) diblock copolymer1H NMR spectras.
Fig. 5 is the mPEG-b-PCL (M that concentration is 10mg/mLmPEG：MPCL=1：1) diblock copolymer is in human breast carcinoma Microphoto record on cell line mcf-7 culture medium in continuous culture a period of time.
Fig. 6 is the mPEG-b-PCL (M that concentration is 1mg/mLmPEG：MPCL=1：1) diblock copolymer is thin in human breast carcinoma Microphoto record on born of the same parents system MCF-7 culture mediums in continuous culture a period of time.
Fig. 7 is the mPEG-b-PCL (M that concentration is 0.1mg/mLmPEG：MPCL=1：1) diblock copolymer is in human breast carcinoma Microphoto record on cell line mcf-7 culture medium in continuous culture a period of time.
Specific embodiment
Reagent：Polyethylene glycol (mPEG, Mn=2000, Aldrich, USA), ε-hexamethylene lactone (ε-CL, density 1.07g/cm3 Alfa Aesar, USA), stannous octoate (Sn (Oct) 2, Sigma, USA), toluene, methyl tertiary butyl ether(MTBE), human breast carcinoma is thin Born of the same parents MCF-7 (ATCC), DMEM cell culture mediums (HyClone), 0.25% trypsase (HyClone), hyclone (Chinese holly), Pen .- Strep dual anti-(HyClone), physiological saline, PBS (phosphate buffer).
Instrument：Toluene azeotropic water removing device, oil bath pan, three-neck flask, condenser pipe, glass stopper, vacuum extractor, nitrogen gas Ball, syringe, Vltrasonic device, reagent rifle, cooling device, Suction filtration device, Reagent Tube, vacuum desiccator, label, mark Pen, assay balance, nuclear magnetic resonance, 96 orifice plates, Tissue Culture Dish, 15mL centrifuge tubes, EVOSFLAuto imaging systems.
With reference to test example and specific embodiment, the present invention is described in further detail.But this should not be interpreted as this hair The scope of bright above-mentioned theme is only limitted to following embodiment, and all technologies realized based on present invention belong to model of the invention Enclose.For the percentage of special instruction is usually percentage by weight in the present invention.
Embodiment 1
Synthesis mPEG-b-PCL (MmPEG：MPCL=1：1)
Test the form that feeds intake：
Polyethylene glycol 1.000g is accurately weighed using assay balance, is added in three-neck flask, 10mL toluene is added, in oil bath pan Azeotropic water removing 2 hours under the conditions of 138 DEG C.0.94mL ε-hexamethylene lactone after cooling, adds appropriate stannous octoate catalyst, plus Enter a magnetic stir bar, add 10mL toluene, three mouths of three-neck flask are used into glass stopper, condenser pipe (condensation respectively Pipe upper end covers a tiny balloons full of nitrogen), vacuumizing joint is sealed, and connects vacuum extractor, opens condenser pipe upper end piston, Vacuumizing joint piston is opened, opening vacuum extractor vacuumize 5 minutes, closes vacuumizing joint piston, closes condensation Pipe upper end piston, closes vacuum extractor, disconnects three-necked bottle and is connected with vacuum extractor, is replaced with a balloon full of nitrogen That balloon, opens condenser pipe upper end piston before.
This three-necked bottle is fixed on iron stand, is placed in oil bath pan, to 138 DEG C, magnetic agitation rotational speed regulation is into for temperature adjustment Speed, reacts 12 hours, if solvent is reduced can be suitably added toluene in course of reaction.After reaction terminates, room temperature is cooled to, Then add 10mL methyl tertiary butyl ether(MTBE)s, ultrasound 10 minutes, ice bath cooling recrystallization 20 minutes carries out suction filtration, collects filter Slag, is put into vacuum desiccator, dries 1 hour, and product is loaded into plastic tube, is weighed, and sticks respective labels.
Fig. 1 is the PEG-PCL diblock copolymer of standard1H NMR spectras.Chemical shift is 3.65 × 10-6 Peak belong to the proton peak of polyethylene glycol segment methylene a, 2.3 × 10-6Triplet belong to proton at c, 4.1 × 10-6 Triplet belong to proton at f, 1.6 × 10-6Multiplet belong to proton at d, and be located at most High-Field 1.4 × 10-6's Multiplet belongs to the proton peak at e.
By the mPEG-b-PCL (M of gainedmPEG：MPCL=1：1) sample is fitted into general 3 microns in nuclear magnetic tube, with syringe plus Enter appropriate deuterochloroform, nuclear magnetic tube is clogged with stopper.MPEG-b-PCL (M are marked with marking penmPEG：MPCL=1：1). Carry out nuclear magnetic resonance.Fig. 2 is mPEG-b-PCL (MmPEG：MPCL=1：1) diblock copolymer1H NMR spectras.
1H NMR (400MHz, DMSO-d6) δ 3.98 (t, J=6.5Hz, 7H), 3.46-3.30 (m, 2H), 3.32 (s, 5H), 3.24 (s,1H), 2.27 (t, J=7.4Hz, 7H), 1.61-1.45 (m, 15H), 1.29 (qd, J=9.6,9.0, 6.0Hz, 9H), 0.89-0.77 (m, 2H)
Nmr analysis result shows that synthetic product is the mPEG-b-PCL (M of targetmPEG：MPCL=1：1) diblock polymer.
Embodiment 1 1：1 1.000 0.94
Embodiment 2 1：4 1.000 3.74
Embodiment 3 1：6 1.000 5.61
Embodiment 2
Synthesis mPEG-b-PCL (MmPEG：MPCL=1：4)
Polyethylene glycol 1.000g is accurately weighed using assay balance, is added in three-neck flask, 10mL toluene is added, in oil bath pan Azeotropic water removing 2 hours under the conditions of 140 DEG C.3.74mL ε-hexamethylene lactone after cooling, adds appropriate stannous octoate catalyst, plus Enter magnetic stir bar, add 10mL toluene, three mouths of three-neck flask are used into glass stopper respectively, condenser pipe is (on condenser pipe One tiny balloons full of nitrogen of end set), vacuumizing joint is sealed, and connects vacuum extractor, opens condenser pipe upper end piston, is beaten Vacuumizing joint piston is opened, opening vacuum extractor vacuumize 5 minutes, closes vacuumizing joint piston, closes condenser pipe Upper end piston, closes vacuum extractor, disconnects three-necked bottle and is connected with vacuum extractor, is replaced it with a balloon full of nitrogen Preceding that balloon, opens condenser pipe upper end piston.This three-necked bottle is fixed on iron stand, is placed in oil bath pan, temperature adjustment To 140 DEG C.Magnetic agitation rotational speed regulation is reacted 12 hours to middling speed, can be suitably added if solvent is reduced in course of reaction Toluene.Reaction is cooled to room temperature after terminating, add 10mL methyl tertiary butyl ether(MTBE)s, and ultrasound 10 minutes is cooled down under ice bath and tied again Brilliant 20 minutes, suction filtration is then carried out, filter residue is loaded into vessel, be put into vacuum desiccator and dry 1 hour, product loaded and is moulded Expects pipe, weighs, and sticks respective labels.
By the mPEG-b-PCL (M of gainedmPEG：MPCL=1：4) sample is fitted into general 3 microns in nuclear magnetic tube, with syringe plus Enter appropriate deuterochloroform, nuclear magnetic tube is clogged with stopper.MPEG-b-PCL (M are marked with marking penmPEG：MPCL=1：4). Carry out nuclear magnetic resonance.Fig. 3 is mPEG-b-PCL (MmPEG：MPCL=1：4) diblock copolymer1H NMR spectras.
mPEG-b-PCL(1:4)
1H NMR (400MHz, DMSO-d6) δ 3.98 (t, J=6.5Hz, 4H), 3.51 (s, 20H), 2.27 (t, J=7.3 Hz, 4H), 1.54 (h, J=7.5Hz, 8H), 1.36-1.23 (m,1H), 1.29 (s, 4H)
Nmr analysis result shows that synthetic product is target mPEG-b-PCL (MmPEG：MPCL=1：4) diblock polymer.
Embodiment 3
Synthesis mPEG-b-PCL (MmPEG：MPCL=1:6)
Polyethylene glycol 1.000g is accurately weighed using assay balance, is added in three-neck flask, 10mL toluene is added, in oil bath pan Azeotropic water removing 2 hours under the conditions of 140 DEG C.5.61mL ε-hexamethylene lactone after cooling, adds appropriate stannous octoate catalyst, plus Enter magnetic stir bar, add 10mL toluene, three mouths of three-neck flask are used into glass stopper respectively, condenser pipe is (on condenser pipe One tiny balloons full of nitrogen of end set), vacuumizing joint is sealed, and connects vacuum extractor, opens condenser pipe upper end piston, is beaten Vacuumizing joint piston is opened, opening vacuum extractor vacuumize 5 minutes, closes vacuumizing joint piston, closes condenser pipe Upper end piston, closes vacuum extractor, disconnects three-necked bottle and is connected with vacuum extractor, is replaced it with a balloon full of nitrogen Preceding that balloon, opens condenser pipe upper end piston.This three-necked bottle is fixed on iron stand, is placed in oil bath pan, temperature adjustment To 140 DEG C, magnetic agitation rotational speed regulation to middling speed is reacted 12 hours, can be suitably added if solvent is reduced in course of reaction Toluene reactions are cooled to room temperature after terminating, and add 10mL methyl tertiary butyl ether(MTBE)s, and ultrasound 10 minutes cools down recrystallization under ice bath 20 minutes, suction filtration is then carried out, filter residue is loaded into vessel, be put into vacuum desiccator and dry 1 hour, product is loaded into plastics Pipe, weighs, and sticks respective labels.
By the mPEG-b-PCL (M of gainedmPEG：MPCL=1：6) sample is fitted into general 3 microns in nuclear magnetic tube, with syringe plus Enter appropriate deuterochloroform, nuclear magnetic tube is clogged with stopper.MPEG-b-PCL (M are marked with marking penmPEG：MPCL=1：6). Carry out nuclear magnetic resonance.Fig. 4 is mPEG-b-PCL (MmPEG：MPCL=1：6) diblock copolymer1H NMR spectras.
mPEG-b-PCL(1:6)
1H NMR(400MHz,DMSO-d6) δ 3.98 (t, J=6.5Hz, 2H), 3.51 (s, 10H), 2.33-2.23 (m, 3H), (m, the 1H) of 1.52 (dh, J=14.0,7.2Hz, 5H), 1.28 (dq, J=13.4,7.5,6.8Hz, 2H), 0.89-0.79
Nmr analysis result shows that synthetic product is the mPEG-b-PCL (M of targetmPEG：MPCL=1：6) diblock polymer.
Fig. 2-4 is contrasted with Fig. 1 respectively, peak position is gone out in nuclear magnetic spectrum and magnetic integration is all consistent with Fig. 1, illustrates embodiment Three kinds of different polycaprolactone content ratio (M of 1-3 synthesisMPEG:MPCL=1:1, MMPEG:MPCL=1:4, MMPEG: MPCL=1:6) PEG-PCL di-block copolymer is all the set goal product, and product is pure very high, It is consistent with expected synthesis purpose.
Test example 1
The cell experiment of mPEG-b-PCL diblock copolymers
The human breast carcinoma cell lines MCF-7 of 1.ATCC purchases is washed once after being melted with 37 DEG C of water-baths rapidly with DMEM culture mediums, 1200rpm is centrifuged 3min, abandons supernatant, adds fresh culture medium, and cell is dispelled into cell suspension, is transferred to added with new In 37 DEG C, 5%CO in the culture dish of fresh culture medium2Cultivated in condition incubator.
2. by the 1 of Preparatory work of experiment:The mPEG-b-PCL materials of 1 ratio are with being configured to 0.1mg/mL, 1mg/mL and 10mg/mL Three solution of concentration, (compound method：MPEG-b-PCL (M are accurately weighed using assay balancemPEG：MPCL=1：1) sample Product 10mg, adds the sample cell of 1.5mL, and deionized water is drawn using imbibition rifle, instills sample cell, is settled to 1mL scales Line, ultrasound is carried out about 20 minutes by this sample cell, is then heated under 40 DEG C of water bath conditions about 5 minutes, and sample is complete Dissolving, that is, obtain C1=10mg/mL mPEG-b-PCL (MmPEG：MPCL=1：1) sample solution；C is drawn using imbibition rifle1=10 mg/mL mPEG-b-PCL(MmPEG：MPCL=1：1) sample solution 0.1mL, adds another an equal amount of sample cell, Imbibition rifle draws deionized water, is settled to 1mL graduation marks, that is, obtain C2=1mg/mL mPEG-b-PCL (MmPEG：MPCL= 1：1) sample solution；C is drawn using imbibition rifle2=1mg/mL mPEG-b-PCL (MmPEG：MPCL=1：1) sample solution 0.1mL, adds another an equal amount of sample cell, imbibition rifle to draw deionized water, be settled to 1mL graduation marks, that is, obtain C3=0.1mg/mL mPEG-b-PCL (MmPEG：MPCL=1：1) sample solution.Then the solution of 3 concentration is pressed respectively 50 μ L/ holes are added in 96 orifice plates, and each concentration sets 3 multiple holes.Physiological saline is used respectively per hole after solution volatilizees naturally 100 μ L are washed 3 times, are dried naturally again standby.
3. cell is long sucks old culture medium when ware bottom is paved with, and with 2mL PBS drip wash once, adds the pancreas eggs of 2mL 0.25% White enzyme is digested, and treats that cell loses original form and becomes bowlder addition complete medium termination digestion, collects cell, 1200rpm Centrifugation 3min, abandons supernatant, and cell into single cell suspension is blown and beaten with new culture medium, and adjustment cell is counted by blood cell counting plate Concentration is 105Individual/mL, is inoculated on 96 orifice plates by 100 μ L/ hole densities, and continuation is cultivated in incubator, every 24h aobvious Micro- Microscopic observation is simultaneously taken pictures.
Propagation coefficient S=W of the cell on culture mediumcs-Wcc(Wcs:Represent the surface energy between cell and culture medium, Wcc：Represent Surface energy between cell and cell).Work as Wcs<Wcc(S<0) when, cell tends to coherent condition；Work as Wcs>Wcc(S>0) When, cell tends to coherent condition.The surface between cell and cell can be reduced in vivo, will depart from cancer cell original Tumour, which results in transfer and the diffusion of cancer cell.Although the surface between cancer cell and cancer cell can be very big, cancer is thin The cytoactive of born of the same parents' aggregate surface is very strong, and cause allows them to depart from original tumour, so as to cause the transfer of cancer cell and expand Dissipate.Three kinds of copolymer solutions of concentration are tested with human breast carcinoma cell lines MCF-7, are clapped once every 24 hours, and 4 are clapped altogether It is secondary, take pictures result as illustrated in figs. 5-7.Wherein, it is 10mg/mL (Fig. 5), 1mg/mL (figures that Fig. 5-7 corresponds respectively to concentration 6), the mPEG-b-PCL (M of 0.1mg/mL (Fig. 7)mPEG：MPCL=1：1) block copolymer is in MCF-7 Microphoto record on MCF-7 culture mediums in continuous culture a period of time.
From Fig. 5-7, the influence approximate trend of three kinds of various concentrations sample solutions to human breast carcinoma cell lines MCF-7 is：The One day, there is not aggregation in cell, and cell is gradually assembled within second day, and cell aggregation in the 3rd day reaches maximum, the 4th day cell Start apoptosis.Show three kinds of block polymers of various concentrations, cell can be effectively suppressed within initial a period of time Adhesion.But, various concentration have certain difference, C again2The effect of=1mg/mL sample solutions is most preferable, C1=10mg/mL, C3The effect of the sample solution of=0.1mg/mL is not ideal.The corresponding cell of sample solution of three kinds of concentration all occurred at the 4th day Apoptosis, reason is exactly that the nutritional ingredient of culture dish was consumed at the 4th day and is over, and cell then starts without nutrition continued growth Apoptosis.
Result shows that self assembly mPEG-b-PCL prepared by the present invention can effectively suppress the adhesion of cancer cell, accordingly MPEG-b-PCL micellas are novel, reliable, safety, can be as the carrier for being insoluble in water medicine, and in cancer Good carrier function and auxiliary therapeutic action is played in target medicine carrier, with huge clinical value.

Claims (6)

1. a kind of diblock polymer of polyethylene glycol crosslinked polycaprolactone, its composition structure is mPEG-b-PCL, and wherein mPEG and PCL molar ratios are 1：0.1~1：10.
2. the diblock polymer of polyethylene glycol crosslinked polycaprolactone as claimed in claim 1, it is characterised in that mPEG and PCL mass ratios are 1：1~1：6.
3. a kind of method for preparing described diblock polymer, comprises the following steps：
（1）Taking polyethylene glycol, is dissolved in toluene, is dehydrated 1-3 hours at 120-150 DEG C；
（2）ε-hexamethylene lactone and stannous octoate, nitrogen is added to protect, 130-160 DEG C is reacted 8-16 hours；
（3）After reaction terminates, room temperature is cooled to, addition methyl tertiary butyl ether(MTBE) is ultrasonic 5-30 minutes, under ice bath, cooling recrystallization 10-30 minutes, suction filtration collects filter residue, and vacuum drying both obtains target product.
4. application of the diblock polymer of above-mentioned polyethylene glycol crosslinked polycaprolactone in treating cancer or tumour medicine is prepared.
5. application process as claimed in claim 5, it is characterised in that application of the diblock polymer of polyethylene glycol crosslinked polycaprolactone in treatment breast cancer medicines are prepared.
6. application process as claimed in claim 5, it is characterised in that application of the diblock polymer of described polyethylene glycol crosslinked polycaprolactone as medicine carrying material in the medicine for the treatment of cancer or tumour.
CN201610494508.0A 2016-06-29 2016-06-29 A kind of mPEG-b-PCL diblock polymer polymer and its application and preparation Active CN106800641B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610494508.0A CN106800641B (en) 2016-06-29 2016-06-29 A kind of mPEG-b-PCL diblock polymer polymer and its application and preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610494508.0A CN106800641B (en) 2016-06-29 2016-06-29 A kind of mPEG-b-PCL diblock polymer polymer and its application and preparation

Publications (2)

Publication Number Publication Date
CN106800641A true CN106800641A (en) 2017-06-06
CN106800641B CN106800641B (en) 2019-03-12

Family

ID=58976086

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610494508.0A Active CN106800641B (en) 2016-06-29 2016-06-29 A kind of mPEG-b-PCL diblock polymer polymer and its application and preparation

Country Status (1)

Country Link
CN (1) CN106800641B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135983A (en) * 2021-04-12 2021-07-20 四川大学华西医院 Antitumor compound and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198083A (en) * 2010-05-27 2011-09-28 四川大学 Micelles and freeze-dried preparations of diblock polymer-supported taxane medicines and preparation and use thereof
CN102670525A (en) * 2012-05-07 2012-09-19 李晓林 Application of ursolic-acid nano medicine-carrying microspheres for treating tumors and preparation
CN104784712A (en) * 2014-12-29 2015-07-22 王巧英 A preparing method of a nanometer polymer micelle carrier integrating diagnosis and treatment
CN104857502A (en) * 2015-04-15 2015-08-26 南昌大学第二附属医院 Vascular endothelial growth factor loaded nano controlled-release compound and a preparation method thereof
CN105362223A (en) * 2015-06-03 2016-03-02 郭玉岩 Method for preparing triblock copolymer micelle of medicine capable of being targeted

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198083A (en) * 2010-05-27 2011-09-28 四川大学 Micelles and freeze-dried preparations of diblock polymer-supported taxane medicines and preparation and use thereof
CN102670525A (en) * 2012-05-07 2012-09-19 李晓林 Application of ursolic-acid nano medicine-carrying microspheres for treating tumors and preparation
CN104784712A (en) * 2014-12-29 2015-07-22 王巧英 A preparing method of a nanometer polymer micelle carrier integrating diagnosis and treatment
CN104857502A (en) * 2015-04-15 2015-08-26 南昌大学第二附属医院 Vascular endothelial growth factor loaded nano controlled-release compound and a preparation method thereof
CN105362223A (en) * 2015-06-03 2016-03-02 郭玉岩 Method for preparing triblock copolymer micelle of medicine capable of being targeted

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113135983A (en) * 2021-04-12 2021-07-20 四川大学华西医院 Antitumor compound and preparation method thereof
CN113135983B (en) * 2021-04-12 2022-06-24 四川大学华西医院 Antitumor compound and preparation method thereof

Also Published As

Publication number Publication date
CN106800641B (en) 2019-03-12

Similar Documents

Publication Publication Date Title
KR102190093B1 (en) Biodegradable amphiphilic polymers specifically targeting ovarian cancer, polymer cyclists prepared therefrom, and uses
CN102906157A (en) Derivatized hyperbranched polyglycerols
CA3009252C (en) Biodegradable amphiphilic polymer, polymeric vesicles prepared therefrom, and application of biodegradable amphiphilic polymer in preparation of medicines for targeted therapy of lung cancer
CN108926531A (en) A kind of reduction and the nano-micelle of pH dual responsiveness and the preparation method and application thereof
US20230096466A1 (en) New method of synthesis of chitosan derivatives and uses thereof
CN110025593A (en) Cell microcapsule, the cell microcapsule for being loaded with anticancer drug, preparation method and application
CN108113977B (en) Preparation method and application of gelatin-loaded berberine hydrochloride nanoparticles encapsulated by erythrocyte membranes
CN110123754B (en) Xanthatin nano micelle targeting dendritic cells, and preparation method and application thereof
CN104116711A (en) pH-sensitive polymeric micelle composition resisting tumor drug resistance
CN106800641A (en) A kind of mPEG-b-PCL diblock polymers polymer and its application and preparation
CN104208704A (en) Preparation method for pH-sensitive carbon nano tube-targeted drug delivery system
CN107349434A (en) A kind of dissaving polymer and its preparation method and application
CN104857502A (en) Vascular endothelial growth factor loaded nano controlled-release compound and a preparation method thereof
US20200093783A1 (en) Preparation and Anti-HepG2 Application for Urushiol-Based pH Response Micelle Encapsulating Paclitaxel
CN107233332A (en) Preparation, activity and the application of GO PLL RGDS/VEGF siRNA target gene medicines
CN110859820A (en) Biocompatible alkaline earth metal peroxide nano preparation, preparation method and application thereof
CN113304325A (en) Injectable and antibacterial dual-functional hydrogel and preparation method and application thereof
US20210069120A1 (en) Composite nanoparticle, preparation method thereof and preparation method of composite nano preparation using thereof
CN109172524A (en) A kind of Puerarin micella and preparation method thereof, puerarin preparation
CN106939075A (en) A kind of hydrophilic polyester and its block copolymer
CN113694217B (en) Pharmaceutical composition containing IL-15 cationic liposome complex and celecoxib liposome and preparation method and application thereof
CN107929262A (en) Ethylenediamine cationized albumin anti-tumor nano grain and its preparation method and application
CN105535988A (en) Preparation method and antitumor enhancement application of dual-targeting delivery chemotherapeutic drug nanosystem
CN108159045A (en) The application of red pineapple flower alkali A and its derivative in prevention or treatment central nervous system disease drug is prepared
CN103263671B (en) Preparation and application of anti-tumor activator nanostructure lipid carrier

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant